ITT Istituto Toscano Tumori (logo)
Ricerca avanzata
[an error occurred while processing this directive]

Ematologia

Unità  di ricerca: U.O. Ematologia Pisa
Azienda Ospedaliera Universitaria Pisana
Via Roma 67 56100 Pisa
Tel: 050/992755
Fax: 050/992755
Responsabile: Mario Petrini

Progetti Specifici

  • Studi sulla malattia minima residua; differenziazione cellule staminali; vaccinoterapia a DNA per LNH; chemioresistenza e polimorfismi; impatto ambientale; fattori di crescita e traduzione del segnale; protocolli terapeutici.

Grants

  • AIL
  • MURST
  • Privati

Collaborazioni

  • altre Unità  I.T.T.
  • altri GISL; GIMEMA; ICGEB Trieste e New Delhi, Numerose Università  Italiane ed Ester

Pubblicazioni (dal 2001)

  1. 169/98-I Interferon-activity in a case of severe autoimmune lymphoproliferative disease S. Ceretelli, M. Petrini, . Galimberti, C. Testi, G. Frizzerea. Ann. Hematol. 80: 49-52; 2001 1,504
  2. 170/99-I Lenograstim and Filgrastim effects on neutrophil mobility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis Azzarà  A., Carulli G., Petrini M. Am. J. Hematol 66: 306-308; 2001
  3. 171/100-I Unusual morphology in a case of large granular cell leukemia.S. Galimberti, R. Riccioni, A. Azzarà, R. Testi, R. Fazzi, M. Petrini Ann. Hematol. 80: 755 - 757; 2001 1,448
  4. 172/101- I Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G; GISL.Haematologica. 86(9):951-8; 2001 I.F.2.560
  5. 173/102I Role of molecular monitoring in autotransplanted patients affected by non Hodgkin's lymphoma. Galimberti S., Marasca R., Caracciolo F., Fazzi R., Papineschi F., Benedetti E ,Guerrini F., Morabito F., Di Renzo N., Federico M., Petrini M., Torelli G. Bone Marrow Transpl. 29(7):581-7. 2002 2,396
  6. 174/103-I Bone and Bone Marrow interactions: Hematological activity of osteoblastic growth peptide (OGP)- derived carboxy-herminal pentapetide. Mobilizing properties on withe blood cells and peripheral blood stem cells in mice. Fazzi R., Testi R., Trasciatti S., Galimberti S., Rosini S., Piras F., L'Abbate G., Conte A., Petrini M. Leuk Res. 26: 19 - 27; 2002 1,504
  7. 175/104-I Bone and Bone Marrow interactions: Hematological activity of osteoblastic growth peptide (OGP)- derived carboxy-herminal pentapetide.II Action on Human Hematopoietic stem cells. Fazzi R., Galimberti S., Testi R., Pacini S., Trasciatti S., Rosini S., Petrini M. Leuk Res. 26(9):839-48; 2002 1,504
  8. 176/105-I Oral cyclophosphamide therapy for patients with residual or relapsed indolent type lymphoma after initial treatment for aggressive lymphomas. A sub group of patients with apparent transformed indolent lymphoma. Riccioni R., Galimberti S., Cervetti G., Fazzi R., Caracciolo F., Petrini M. Leukem Lymphoma. 43: 1803 - 1806;2002 I.F. 1,335
  9. 177/106-I Thrombocytopenic purpura: an unusual complication of eradication therapy for helicobacter pylori Marchi S., Bellini M., Costa F., De Bortoli N., Petrini M., Maltinti G Dig Liver Dis 34: 665 - 667; 2002
  10. 178/107-I Efficacy and Toxicity of liposomal daunorubicin included in PVABEC regimen for aggressive NHL of the elderly Cervetti G., Caracciolo F., Cecconi N., Azzarà  A., Petrini M. Leukemia and Lymphoma 44: 465-469; 2003 I.F. 1,335
  11. 179/ 108-I Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. Fazzi R, Pacini S, Testi R, Azzara A, Galimberti S, Testi C, Trombi L, Metelli MR, Petrini M. Br J Haematol 121(1):76-85; 2003-04-15 I.F. 3,052
  12. 180/109-I Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzara A, Martino M, Benedetti E, Di Raimondo F, Petrini M. Br J Haematol 120(3):405-12; 2003 I.F. 3,052
  13. 181/110-I Mitoxantrone, prednisone, pentostatin and bleomicin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results od a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL) Federico M, Callea V, Danesi R, Montanini A, Di Renzo N, Petrini M, Del Tacca M, Sirotti MA, Santacroce G, Bagnulo A, Dell'Olio M, Brugiatelli M Cancer Therapy 1: 1-8; 2003 I.F.
  14. 182/111-I Quantitative molecular evaluation in autotransplant programs for follicula lymphoma: efficacy of in vivo purging by Rituximab Galimberti S, Guerrini F, Morabito F, Palumbo GA, Di Raimondo F, Papineschi F, Caracciolo F, Fazzi R, Cernetti G, Cuzzocrea A, Petrini M Bone Marrow transplant 32: 57-63; 2003 I.F. 2,378
  15. 183/112-I. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukaemia Galimberti S., Rossi A., Palumbo G.A., Morabito F., Guerrini F., Vincelli I., Fazzi R., Santini V., Petrini M. Anticancer Res 23: 3419 - 3426; 2003 I.F. 1,447
  16. 184/113-I Early reappearance of primary solid cancer in patients treated with purine analogs. Fazzi R, Caracciolo F, Galimberti S, Petrini M. J Chemother. 2003 Aug;15(4):406-8 I.F. 0,82
  17. 185/114-I The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. Galimberti S, Testi R, Guerrini F, Fazzi R, Petrini M. J Chemother. 2003 Aug;15(4):374-9 I.F. 0,82
  18. 186/115-I Effect of lecithin on epicutaneous absorption of diclofenac epolamine. Conte A, Ronca G, Petrini M, Mautone G. Drugs Exp Clin Res. 2002;28(6):249-55 I.F. 0,60
  19. 187/116-I. Lithium effects on neutrophil motility in Shwachman-Diamond syndrome: evaluation by computer-assisted image analysis. Azzara A, Carulli G, Petrini M Br J Haematol. 2003 Oct;123(2):369-70. I.F. 3,267
  20. 188/117-I Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M.Hematol Oncol. 2003 Dec;21(4):163-8. . 3,105
  21. 189/118-I Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. Orciuolo E, Azzara A, Bandini G, Galimberti S, Bonifazi F, Fazzi R, Petrini M Bone Marrow Transplant. 2004 Apr;33(8):859-61. I.F. 2,172
  22. 190/119-I A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings. Papineschi F, Benedetti E, Galimberti S, Caracciolo F, Fazzi R, Petrini M.Bone Marrow Transplant. 2004 Mar;33(6):659-60. I.F. 2,172
  23. 191/120-I Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, Petrini M. Eur J Haematol. 2004 Jan;72(1):45-51. I.F. 1,174
  24. 192/121-I : Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib. Cervetti G, Galimberti S, Fazzi R, Papineschi F, Azzara A, Simi P, Petrini M. Eur J Clin Invest. 2004 Mar;34(3):243-4. I.F. 2,346
  25. 193/122-I Expansion of TcRalphabeta+CD3+CD4-CD8- (CD4/CD8 double-negative) T lymphocytes in a case of staphylococcal toxic shock syndrome. Carulli G, Lagomarsini G, Azzara A, Testi R, Riccioni R, Petrini M. Acta Haematol. 2004;111(3):163-7. I.F. 1,847
  26. 194/123-I Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, Petrini M.Leuk Res. 2004 Apr;28(4):367-72. I.F. 2,333
  27. 195/124-I Bilateral primary renal lymphoma treated by surgery and chemotherapy. Cupisti A, Riccioni R, Carulli G, Paoletti S, Tognetti A, Meola M, Francesca F, Barsotti G, Petrini M Nephrol Dial Transplant. 2004 Jun;19(6):1629-33. I.F. 2,607
  28. 196/125-I Bone and bone marrow interactions: hematologiacal activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocitemia Fazzi R, Galimberti S, Pacini C, Testi R, Azzarà  A, Orciuolo E, Trombi L, Metalli M.R, Petrini M.Leuk Res. 2004 Oct;28(10):1097-105 I.F. 2,3333
  29. 197 126-I Role of low-dose 2CdA in refractory or resistant lymphoplasmocytic lymphoma Cervett G, Galimberti S, Cecconi N, Caracciolo F, Petrini M J Chemother 16: 388 - 391; 2004 I.F. 0,82
  30. 198/127-Iquantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia. Efficacy of in vivo purging by Alemtuzumab (Campath-1H) Galimberti S, Cervetti G, Cecconi N, Fazzi R, Guerrini F, Manetti C, Caracciolo F, Petrini M J Immunother. 2004 Sep-Oct;27(5):389-93 I.F. 3,983
  31. 199/128 Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M. Eur J Haematol. 2004 Dec;73(6):412-7.
  32. 200/129 Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA. Mattii L, Fazzi R, Moscato S, Segnani C, Pacini S, Galimberti S, D'Alessandro D, Bernardini N, Petrini M.J Cell Biochem. 2004 Dec 15;93(6):1231-41
  33. 201/130 Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C, Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M. Leuk Res. 2005 Aug;29(8):961-6.
  34. 202/131 Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA. Mattii L, Azzara A, Fazzi R, Carulli G, Chimenti M, Cecconi N, Galimberti S, Petrini M. Leuk Res. 29: 1285-1292; 2005
  35. 203/132 Imatinib therapy in Hypereosinophilic Syndrome: A case of molecular remission. Cervetti G, Galimberti S, Carulli G, Petrini M Leuk Res. 2005 Sep;29(9):1097-8.
  36. 204/133 Primary Lymphoma of the bladder: case report. Riccioni R, Carulli G, De Maria M, Pacini S, Gagno C, Selli C, Petrini M Am. J. Hematol 80: 1-2; 2005
  37. 205/134 Fluoroquinolone resistance in hemopoietic syem cell transplant recipients with infectious complications Bonadio M, Morelli G, Mori S, Riccioni R, Papineschi F, Petrini M Biomed Pharmacother. 2005 Oct;59(9):511-6. I.F .1,826
  38. 206/135I Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy Carulli G, Canigiani S, Volpini M, Ciancia EM, Galimberti S, Zucca A, Marini A, Buda G, Petrini M. Recenti Prog Med. 2005 Jun;96(6):284-90.
  39. 207/136I Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M. Cancer Genet Cytogenet. 2005 Oct 1;162(1):57-62.
  40. 208/137I Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy. Orciuolo E, Fazzi R, Galimberti S, Testi C, Azzara' A, Carulli G, Petrini M. Leuk Res. 2006 Mar;30(3):349-53.
  41. 209/138I Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, Fazzi R, Ciabatti E, Martino M, Cuzzola M, Console G, Iacopino P, Petrini M. Leuk Res. 2006 May;30(5):529-35.
  42. 210/138I Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Galetta F, Franzoni F, Cervetti G, Cecconi N, Carpi A, Petrini M, Santoro G. Biomed Pharmacother. 2005 Dec;59(10):541-4.
  43. 211/139I High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M.Clin Exp Rheumatol. 2005 Nov-Dec;23(6):877-80.
  44. 212/139I Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Galimberti S, Benedetti E, Morabito F, Fazzi R, Pacini S, Andreazzoli F, Martino M, Iacopino P, Petrini M.Transpl Immunol. 2005 Dec;15(2):173-7.
  45. 213/140I Granulocytic sarcoma and subsequent acute leukemia recurrence with different biologic characteristics 5 years after allogeneic bone marrow transplantation for acute myeloid leukemia. Pelosini M, Benedetti E, Galimberti S, Caracciolo F, Petrini M, Fazzi R, Andreazzoli F, Papineschi F. Bone Marrow Transplant. 2006 Mar 20;
  46. 214/ 141I Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Bolli N, Galimberti S, Martelli MP, Tabarrini A, Roti G, Mecucci C, Martelli MF, Petrini M, Falini B. Lancet Oncol. 2006 Apr;7(4):350-2.